Investigators reported results from the first randomized controlled trial of office-based laser photocoagulation to standard TURBT for low-grade Ta bladder tumors.

Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated beneficial responses. Patients with recurrent low-grade intermediate-risk ...

Zusduri demonstrated a 72.2% 24-month response durability in LG-IR-NMIBC patients, leading to FDA approval as a non-surgical treatment option. The ENVISION trial enrolled 240 patients, focusing on ...

Presents 18-month duration of response (DOR) data from the ENVISION study Analyzes the impact of tumor burden or focality in recurrent LG-IR-NMIBC, a substudy from ENVISION Reports ENVISION and ATLAS ...

A phase II prospective, open-label, multi-center, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) pts: SSANTROP (APRO07-2022).

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen (NASDAQ: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced ...

Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone WILMINGTON, Del.-- ...

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial This pragmatic, prospective observational cohort study was designed ...

President and CEO Liz Barrett outlined the company’s urothelial cancer focus and provided an update on the commercial launch of its recently approved bladder cancer therapy during a fireside chat. RTG ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...